AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9785597 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-compatible headholder and modified MR-couch
Number of subjects: 75
Study 7637825 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) and chemotherapy (ChT) containing cisplatinum and 5-fluorouracil (5-FU)
Number of subjects: 30
Study 2673161 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 48
Study 2673161 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 48
Study 880567 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate high dose (0.06 mg/kg/dose)
Number of subjects: 239
Study 880567 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate low dose (0.2 mg/kg/dose)
Number of subjects: 239
Study 880567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 880567 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate high dose and low dose
Number of subjects: 239
Study 880567 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 239
Study 31533443 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair Yoga (CY)
Number of subjects: 31
Study 31533443 — intervention group
Group type: COMPARATOR
Intervention: Music Intervention (MI)
Number of subjects: 31
Study 31533443 — intervention group
Group type: COMPARATOR
Intervention: Chair-Based Exercise (CBE)
Number of subjects: 31
Study 30311691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg
Number of subjects: 464
Study 30311691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 28419315 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CSF neutrophil counts among HIV-uninfected patients
Number of subjects: 608
Study 28419315 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CSF to blood glucose ratio among HIV-uninfected patients
Number of subjects: 608
Study 28419315 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF culture positivity among HIV-uninfected patients
Number of subjects: 608
Study 28419315 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood neutrophilia among HIV-uninfected patients
Number of subjects: 608
Study 28419315 — intervention group
Group type: EXPERIMENTAL
Intervention: LTA4H promoter polymorphism
Number of subjects: 608
Study 25240629 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid eye drops (0.5% loteprednol etabonate) 4 times daily for 15 days
Number of subjects: 75
Study 25240629 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 75
Study 22829151 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA-biofeedback group (N = 13)
Number of subjects: 26
Study 22829151 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual, N = 13)
Number of subjects: 26
Study 20923251 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP/heparin plaster
Number of subjects: 430
Study 20923251 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP plaster
Number of subjects: 430
Study 20923251 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 430
Study 19258615 — intervention group
Group type: EXPERIMENTAL
Intervention: Firebreak skin graft
Number of subjects: 79
Study 19258615 — intervention group
Group type: COMPARATOR
Intervention: Fasciectomy
Number of subjects: 79
Study 17464237 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone (75 mg of isoflavone conjugates/day)
Number of subjects: 0
Study 17464237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16739361 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release oxycodone
Number of subjects: 0
Study 16739361 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 11304094 — intervention group
Group type: EXPERIMENTAL
Intervention: Community action intervention involving formation of community committees and utilization of access-point networks to initiate and maintain intervention strategies.
Number of subjects: 0
Study 11304094 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study 9646650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal ketamine 0.25 mg/kg
Number of subjects: 60
Study 9646650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal ketamine 5 mg/kg
Number of subjects: 60
Study 9646650 — intervention group
Group type: COMPARATOR
Intervention: Nasal midazolam
Number of subjects: 60
Study 8709686 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT plus ddl (400 mg per day)
Number of subjects: 3207
Study 8709686 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT plus ddC (2.25 mg per day)
Number of subjects: 3207
Study 8709686 — intervention group
Group type: COMPARATOR
Intervention: AZT (600 mg per day) alone
Number of subjects: 3207
Study 8709686 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT plus ddl or ddC
Number of subjects: 3207
Study 2321571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (1500 mg total, three times daily with meals for 5.5 weeks)
Number of subjects: 11
Study 2321571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2321571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 11
Study 6991089 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 425
Study 30771684 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezial Denervation
Number of subjects: 45
Study 30771684 — intervention group
Group type: COMPARATOR
Intervention: Trapeziectomy
Number of subjects: 45
Study 28266878 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalisation message (using recipient's first name)
Number of subjects: 112
Study 28266878 — intervention group
Group type: COMPARATOR
Intervention: Feedback message (on personal state)
Number of subjects: 112
Study 28266878 — intervention group
Group type: COMPARATOR
Intervention: Adapted message (to recipient's value)
Number of subjects: 112
Study 28266878 — intervention group
Group type: COMPARATOR
Intervention: Generic health message (control condition)
Number of subjects: 112
Study 25471276 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional androgen deprivation therapy (ADT)
Number of subjects: 392
Study 25471276 — intervention group
Group type: COMPARATOR
Intervention: HDR brachytherapy (HDR-BT) and external beam radiotherapy (EBRT) without ADT
Number of subjects: 392
Study 25471276 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR-BT and EBRT with ADT
Number of subjects: 392
Study 23712683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tool held in peripersonal space (near the body; tool held horizontally)
Number of subjects: 0
Study 23712683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tool held in extrapersonal space (beyond arms' reach; tool held straight)
Number of subjects: 0
Study 23712683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-tool practice in a hockey-like game prior to the task
Number of subjects: 0
Study 23712683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-tool practice constrained to extrapersonal space
Number of subjects: 0
Study 21441418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft
Number of subjects: 208
Study 21441418 — intervention group
Group type: COMPARATOR
Intervention: Fresh-frozen hamstring tendon allograft
Number of subjects: 208
Study 19587642 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐800,569 (30‐1,800 mg once daily for 14 days)
Number of subjects: 0
Study 19587642 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐800,569 (1,800 mg)
Number of subjects: 0
Study 19587642 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐800,569 (higher doses)
Number of subjects: 0
Study 17802984 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive telephone-based disease management programme including interactive sessions and telephonic helpline.
Number of subjects: 50
Study 17802984 — intervention group
Group type: COMPARATOR
Intervention: Control group managed in the heart failure clinic without additional interventions.
Number of subjects: 50
Study 15055997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg once daily
Number of subjects: 20
Study 15055997 — intervention group
Group type: EXPERIMENTAL
Intervention: TBC3711 (7z)
Number of subjects: 20
Study 11802677 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate biofeedback
Number of subjects: 35
Study 11802677 — intervention group
Group type: COMPARATOR
Intervention: Verbal control instructions
Number of subjects: 35
Study 8616576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-directed transbronchial needle aspiration (USTBNA)
Number of subjects: 80
Study 8616576 — intervention group
Group type: COMPARATOR
Intervention: Standard transbronchial needle aspiration (TBNA)
Number of subjects: 80
Study 1467292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (50 mg/day)
Number of subjects: 58
Study 1467292 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (400 mg/day)
Number of subjects: 58
Study 6532139 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 0
Study 6532139 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations about intoxication
Number of subjects: 0
Study 6532139 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31339438 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to estimated total costs of different screening strategies
Number of subjects: 267
Study 31339438 — intervention group
Group type: COMPARATOR
Intervention: No exposure to estimated total costs
Number of subjects: 267
Study 30011798 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas for Health and Wellness intervention
Number of subjects: 140
Study 26525882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal stent
Number of subjects: 8
Study 26525882 — intervention group
Group type: COMPARATOR
Intervention: Standard nCPAP-titration
Number of subjects: 8
Study 24462034 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver
Number of subjects: 26
Study 24462034 — intervention group
Group type: COMPARATOR
Intervention: Standard medications
Number of subjects: 26
Study 22990619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (60-120 mg/day)
Number of subjects: 107
Study 22990619 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 107
Study 19781131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100 microg or 4000 IU daily for 6 months)
Number of subjects: 81
Study 19781131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 17118669 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic surgery (VATS)
Number of subjects: 42
Study 17118669 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 42
Study 15906590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release formulation of bupropion in fasting state
Number of subjects: 49
Study 15906590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release formulation of bupropion after high fat meal
Number of subjects: 49
Study 11872895 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus of 0.25 mg/kg body weight
Number of subjects: 74
Study 11872895 — intervention group
Group type: COMPARATOR
Intervention: Standard antithrombotic medication (aspirin, clopidogrel, and heparin) without abciximab
Number of subjects: 74
Study 10101324 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft biomechanical orthoses
Number of subjects: 0
Study 10101324 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid biomechanical orthoses
Number of subjects: 0
Study 10101324 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biomechanical orthoses)
Number of subjects: 0
Study 7536867 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based longitudinal study of BPH
Number of subjects: 0
Study 1827602 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 0
Study 1827602 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 0
Study 7153164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 31
Study 7153164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30732609 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical high-in-sugar label shaped like a stop sign
Number of subjects: 512
Study 30732609 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based warning label
Number of subjects: 512
Study 30732609 — intervention group
Group type: COMPARATOR
Intervention: No FOP label (control)
Number of subjects: 512
Study 28482053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Intervention Program (SIP)
Number of subjects: 42
Study 28482053 — intervention group
Group type: COMPARATOR
Intervention: Information-only control (IC)
Number of subjects: 42
Study 26314508 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive remediation therapy (CRT), 40 sessions
Number of subjects: 104
Study 26314508 — intervention group
Group type: COMPARATOR
Intervention: Musical and Dancing Therapy (MDT), therapeutic contact-matched
Number of subjects: 104
Study 26314508 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive remediation therapy (CRT)
Number of subjects: 104
Study 26314508 — intervention group
Group type: COMPARATOR
Intervention: Musical and Dancing Therapy (MDT)
Number of subjects: 104
Study 23937306 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseus(®) (new bovine xenograft)
Number of subjects: 20
Study 23937306 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Oss(®) (commercially available bovine xenograft)
Number of subjects: 20
Study 22265857 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS + pranlukast
Number of subjects: 25
Study 22265857 — intervention group
Group type: COMPARATOR
Intervention: ICS + LABA
Number of subjects: 25
Study 19444058 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-door laminoplasty
Number of subjects: 40
Study 19444058 — intervention group
Group type: COMPARATOR
Intervention: French-door laminoplasty
Number of subjects: 40
Study 19444058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17456286 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-out of an ultrasound image of their carotid artery showing atherosclerotic plaque alongside an image of a disease-free artery
Number of subjects: 23
Study 17456286 — intervention group
Group type: COMPARATOR
Intervention: Routine verbal feedback
Number of subjects: 23
Study 15179104 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing correction (group I)
Number of subjects: 55
Study 15179104 — intervention group
Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 55
Study 11293557 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated 50-mg sumatriptan tablets
Number of subjects: 56
Study 11293557 — intervention group
Group type: COMPARATOR
Intervention: Conventional 50-mg sumatriptan tablets
Number of subjects: 56
Study 9497189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed infants
Number of subjects: 1450
Study 9497189 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominantly breast-fed infants
Number of subjects: 1450
Study 9497189 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially breast-fed infants
Number of subjects: 1450
Study 9497189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully weaned infants
Number of subjects: 1450
Study 9497189 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially breast-fed and fully weaned infants
Number of subjects: 1450
Study 9497189 — intervention group
Group type: COMPARATOR
Intervention: Exclusively and predominantly breast-fed infants
Number of subjects: 1450
Study 8071850 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (0, 0.5, 1.0 or 2.0 mg/70 kg)
Number of subjects: 12
Study 8071850 — intervention group
Group type: COMPARATOR
Intervention: Morphine (10 mg/70 kg)
Number of subjects: 12
Study 8071850 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 12
Study 8071850 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 12
Study 8071850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both butorphanol and morphine
Number of subjects: 12
Study 2964984 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 148
Study 2964984 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 148
Study 30328169 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical conditioning program (60-min session, 3 days/week for the duration of pregnancy)
Number of subjects: 120
Study 30328169 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical conditioning program
Number of subjects: 120
Study 30328169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 120
Study 28479216 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy and Holistic Health Recovery Program for Malaysia (HHRP-M)
Number of subjects: 0
Study 28479216 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy alone
Number of subjects: 0
Study 28479216 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic Health Recovery Program for Malaysia (HHRP-M) alone
Number of subjects: 0
Study 28479216 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25756517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 117
Study 25756517 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 117
Study 25756517 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate plus 5-Fluorouracil (5-FU)
Number of subjects: 117
Study 22119148 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS)
Number of subjects: 269
Study 22119148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 20186295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg(‐1)
Number of subjects: 30
Study 20186295 — intervention group
Group type: COMPARATOR
Intervention: Propofol 0.5 mg.kg(‐1)
Number of subjects: 30
Study 17663102 — intervention group
Group type: EXPERIMENTAL
Intervention: Puncturing with needles in alignment at the hairline region
Number of subjects: 120
Study 17663102 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Duxil (control group)
Number of subjects: 120
Study 16135001 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI) treatment with a maximum dose of 250 ml cow's milk or 4.5 g lyophilized hen's egg protein; daily maintenance dose of 100 ml cow's milk or 2.5 g hen's egg protein
Number of subjects: 3
Study 16135001 — intervention group
Group type: EXPERIMENTAL
Intervention: SOTI treatment
Number of subjects: 3
Study 16135001 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular allergen intake
Number of subjects: 3
Study 12406811 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV voluntary counseling and testing (VCT)
Number of subjects: 1634
Study 10439984 — intervention group
Group type: EXPERIMENTAL
Intervention: GP input into discharge planning (test group)
Number of subjects: 364
Study 10439984 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge planning (control group)
Number of subjects: 364
Study 7782117 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once daily
Number of subjects: 0
Study 7782117 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 0
Study 7782117 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin and Azithromycin
Number of subjects: 0
Study 2222246 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-1 treatment (100 mg by daily intramuscular injection for 12 weeks)
Number of subjects: 46
Study 2222246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 348131 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 24
Study 348131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30829777 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injection
Number of subjects: 19
Study 30829777 — intervention group
Group type: COMPARATOR
Intervention: Control (sterile normal saline)
Number of subjects: 19
Study 30623901 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular human dermal allograft (MegaDerm®)
Number of subjects: 60
Study 30623901 — intervention group
Group type: COMPARATOR
Intervention: Autologous tragal perichondrium
Number of subjects: 60
Study 26346640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 37
Study 26346640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study 24443385 — intervention group
Group type: EXPERIMENTAL
Intervention: Social connection messages
Number of subjects: 0
Study 24443385 — intervention group
Group type: EXPERIMENTAL
Intervention: Social change messages
Number of subjects: 0
Study 24443385 — intervention group
Group type: COMPARATOR
Intervention: Non-targets
Number of subjects: 0
Study 22759327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine at 10 mg t.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (LFT-AM)
Number of subjects: 52
Study 22759327 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole at 10 mg b.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (RPZ-AM)
Number of subjects: 52
Study 19339001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed (M) group: rFSH and cetrorelix mixed immediately before administration
Number of subjects: 140
Study 19339001 — intervention group
Group type: COMPARATOR
Intervention: Separate (S) group: rFSH and cetrorelix administered separately
Number of subjects: 140
Study 18844696 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg CP‐481715 TID
Number of subjects: 40
Study 18844696 — intervention group
Group type: COMPARATOR
Intervention: 3000 mg CP‐481715 QD
Number of subjects: 40
Study 18844696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TID and QD)
Number of subjects: 40